Clinical Trial Update: Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

This document notes the completion of a Phase 2/3 clinical trial comparing celecoxib (Celebrex) to placebo in men with recurrent prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CELEBREX (Celecoxib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED